Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
After ZW171's exit, ZW251 enters the clinic.
The company’s matching strategy for CB-010 will soon be put to the test.
After Astra's EsoBiotec takeover the battle for uniqueness begins.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
While Sutro shows why it’s shelved luvelta-T.
The company buys Belgium’s EsoBiotec for $425m.
